Patents by Inventor Ariane VOLKMANN

Ariane VOLKMANN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods and compositions for inducing protective immunity against filovirus infection
    Patent number: 11918639
    Abstract: The present invention provides compositions, vaccines and methods for inducing protective immunity against filovirus infection, particularly protective immunity against infection of one or more subtypes of Ebola viruses and Marburg virus.
    Type: Grant
    Filed: October 11, 2021
    Date of Patent: March 5, 2024
    Assignees: Bavarian Nordic A/S, Janssen Vaccines & Prevention B.V., The United States of America, as represented by The Secretary, Department of Health and Human Service
    Inventors: Ariane Volkmann, Robin Steigerwald, Ulrike Dirmeier, Maria Grazia Pau, Benoit Christophe Stephan Callendret, Lucy A. Ward
  • Multivalent recombinant modified vaccinia virus ankara (MVA) vector encoding filovirus immunogens
    Patent number: 11338030
    Abstract: The present invention relates to an improved filovirus vaccine comprising a recombinant modified vaccinia virus Ankara-based (MVA-based) vaccine against filovirus infection and to related products, methods and uses. Specifically, the present invention relates to genetically engineered (recombinant) MVA and FPV vectors comprising at least one heterologous nucleotide sequence encoding an antigenic determinant of a Marburg virus (MARV) or Ebola virus glycoprotein. Specifically, the invention relates to recombinant MVA comprising Ebola virus glycoprotein and virion protein 40. The invention also relates to products, methods and uses thereof as well as prime/boost regimens of MVA and genetically engineered (recombinant) FPV, e.g., suitable to induce a protective immune response in a subject.
    Type: Grant
    Filed: February 27, 2020
    Date of Patent: May 24, 2022
    Assignee: Bavarian Nordic A/S
    Inventors: Ariane Volkmann, Robin Steigerwald, Hubertus Hochrein, Ulrike Dirmeier, Henning Lauterbach, Jürgen Hausmann
  • METHODS AND COMPOSITIONS FOR INDUCING PROTECTIVE IMMUNITY AGAINST FILOVIRUS INFECTION
    Publication number: 20220088170
    Abstract: The present invention provides compositions, vaccines and methods for inducing protective immunity against filovirus infection, particularly protective immunity against infection of one or more subtypes of Ebola viruses and Marburg virus.
    Type: Application
    Filed: October 11, 2021
    Publication date: March 24, 2022
    Inventors: Ariane VOLKMANN, Robin STEIGERWALD, Ulrike DIRMEIER, Maria Grazia PAU, Benoit Christophe Stephan CALLENDRET, Lucy A. WARD
  • Methods and compositions for inducing protective immunity against filovirus infection
    Patent number: 11173201
    Abstract: The present invention provides compositions, vaccines and methods for inducing protective immunity against filovirus infection, particularly protective immunity against infection of one or more subtypes of Ebola viruses and Marburg virus.
    Type: Grant
    Filed: October 17, 2019
    Date of Patent: November 16, 2021
    Assignees: Bavarian Nordic A/S, Janssen Vaccines & Prevention B.V., The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Ariane Volkmann, Robin Steigerwald, Ulrike Dirmeier, Maria Grazia Pau, Benoit Christophe Stephan Callendret, Lucy A. Ward
  • Methods and compositions for inducing protective immunity against a marburg virus infection
    Patent number: 10925956
    Abstract: Compositions, vaccines and methods using a combination of adenovirus vectors and MVA vectors for inducing protective immunity against a Marburg virus infection are described.
    Type: Grant
    Filed: July 14, 2017
    Date of Patent: February 23, 2021
    Assignees: Janssen Vaccines & Prevention B.V., Bavarian Nordic A/S
    Inventors: Benoit Christophe Stephan Callendret, Ramon Roozendaal, Jutta Sytske Hartkoorn-Pasma, Ariane Volkmann, Robin Steigerwald, Ulrike Dirmeier
  • Recombinant Modified Vaccinia Virus Ankara (MVA) Filovirus Vaccine
    Publication number: 20200268872
    Abstract: The present invention relates to an improved filovirus vaccine comprising a recombinant modified vaccinia virus Ankara-based (MVA-based) vaccine against filovirus infection and to related products, methods and uses. Specifically, the present invention relates to genetically engineered (recombinant) MVA and FPV vectors comprising at least one heterologous nucleotide sequence encoding an antigenic determinant of a Marburg virus (MARV) or Ebola virus glycoprotein. Specifically, the invention relates to recombinant MVA comprising Ebola virus glycoprotein and virion protein 40. The invention also relates to products, methods and uses thereof as well as prime/boost regimens of MVA and genetically engineered (recombinant) FPV, e.g., suitable to induce a protective immune response in a subject.
    Type: Application
    Filed: February 27, 2020
    Publication date: August 27, 2020
    Applicant: Bavarian Nordic A/S
    Inventors: Ariane Volkmann, Robin Steigerwald, Hubertus Hochrein, Ulrike Dirmeier, Henning Lauterbach, Jürgen Hausmann
  • Use of oil and water emulsions for increasing B cell responses with modified Vaccinia Ankara virus
    Patent number: 10653766
    Abstract: The invention relates to compositions, uses, and methods for inducing an immune response against a vaccinia virus. The addition of an oil and water emulsion to MVA can vastly increase the B cell response and particularly neutralizing antibodies against vaccinia virus and encoded recombinant antigens. Thus, the addition of an oil and water emulsion to MVA can increase the protective immune response. The invention encompasses administering a dose of an MVA in an oil and water emulsion to an animal, especially a human.
    Type: Grant
    Filed: March 12, 2015
    Date of Patent: May 19, 2020
    Assignee: Bavarian Nordic A/S
    Inventors: Cédric Cheminay, Robin Steigerwald, Ariane Volkmann
  • Recombinant modified vaccinia virus Ankara (MVA) multivalent filovirus immunogenic compositions and methods of use
    Patent number: 10576141
    Abstract: The present invention relates to an improved filovirus vaccine comprising a recombinant modified vaccinia virus Ankara-based (MVA-based) vaccine against filovirus infection and to related products, methods and uses. Specifically, the present invention relates to genetically engineered (recombinant) MVA and FPV vectors comprising at least one heterologous nucleotide sequence encoding an antigenic determinant of a Marburg virus (MARV) or Ebola virus glycoprotein. Specifically, the invention relates to recombinant MVA comprising Ebola virus glycoprotein and virion protein 40. The invention also relates to products, methods and uses thereof as well as prime/boost regimens of MVA and genetically engineered (recombinant) FPV, e.g., suitable to induce a protective immune response in a subject.
    Type: Grant
    Filed: September 3, 2015
    Date of Patent: March 3, 2020
    Assignee: Bavarian Nordic A/S
    Inventors: Ariane Volkmann, Robin Steigerwald, Hubertus Hochrein, Ulrike Dirmeier, Henning Lauterbach, Jürgen Hausmann Hausmann
  • Methods and compositions for inducing protective immunity against filovirus infection
    Patent number: 10561721
    Abstract: The present invention provides compositions, vaccines and methods for inducing protective immunity against filovirus infection, particularly protective immunity against infection of one or more subtypes of Ebola viruses and Marburg virus.
    Type: Grant
    Filed: September 3, 2015
    Date of Patent: February 18, 2020
    Assignees: Bavarian Nordic A/S, Janssen Vaccines & Prevention B.V., The United States of America, as represented by The Secretary, Department of Health and Human Services
    Inventors: Ariane Volkmann, Robin Steigerwald, Ulrike Dirmeier, Maria Grazia Pau, Benoit Christophe Stephan Callendret, Lucy A. Ward
  • Methods and compositions for enhancing immune responses
    Patent number: 10561722
    Abstract: Compositions and methods are described for generating an improved effective immune response against an immunogen in humans. The enhanced immune response, is obtained by using an MVA vector as a prime and an adenovirus vector as a boost and is characterized by a high level of antibody response specific to the immunogen, and an enhanced cellular immune response. The compositions and methods can be used to provide a protective immunity against a disease, such as an infection of one or more subtypes of Ebola and Marburg filoviruses, in humans.
    Type: Grant
    Filed: September 3, 2015
    Date of Patent: February 18, 2020
    Assignees: Bavarian Nordic A/S, Janssen Vaccines & Prevention B.V., The United States of America, as represented by The Secretary, Department of Health and Human Services
    Inventors: Ariane Volkmann, Robin Steigerwald, Ulrike Dirmeier, Benoit Christophe Stephan Callendret, Macaya Julie Douoguih, Lucy A. Ward
  • METHODS AND COMPOSITIONS FOR INDUCING PROTECTIVE IMMUNITY AGAINST FILOVIRUS INFECTION
    Publication number: 20200038500
    Abstract: The present invention provides compositions, vaccines and methods for inducing protective immunity against filovirus infection, particularly protective immunity against infection of one or more subtypes of Ebola viruses and Marburg virus.
    Type: Application
    Filed: October 17, 2019
    Publication date: February 6, 2020
    Inventors: Ariane VOLKMANN, Robin STEIGERWALD, Ulrike DIRMEIER, Maria Grazia PAU, Benoit Christophe Stephan CALLENDRET, Lucy A. WARD
  • METHODS AND COMPOSITIONS FOR INDUCING PROTECTIVE IMMUNITY AGAINST A MARBURG VIRUS INFECTION
    Publication number: 20190224301
    Abstract: Compositions, vaccines and methods using a combination of adenovirus vectors and MVA vectors for inducing protective immunity against a Marburg virus infection are described.
    Type: Application
    Filed: July 14, 2017
    Publication date: July 25, 2019
    Inventors: Benoit Christophe Stephan CALLENDRET, Ramon ROOZENDAAL, Jutta Sytske HARTKOORN-PASMA, Ariane VOLKMANN, Robin STEIGERWALD, Ulrike DIRMEIER
  • METHODS AND COMPOSITIONS FOR ENHANCING IMMUNE RESPONSES
    Publication number: 20170340721
    Abstract: Compositions and methods are described for generating an improved effective immune response against an immunogen in humans. The enhanced immune response, is obtained by using an MVA vector as a prime and an adenovirus vector as a boost and is characterized by a high level of antibody response specific to the immunogen, and an enhanced cellular immune response. The compositions and methods can be used to provide a protective immunity against a disease, such as an infection of one or more subtypes of Ebola and Marburg filoviruses, in humans.
    Type: Application
    Filed: September 3, 2015
    Publication date: November 30, 2017
    Inventors: Ariane VOLKMANN, Robin STEIGERWALD, Ulrike DIRMEIER, Benoit Christophe Stephan CALLENDRET, Macaya Julie DOUOGUIH, Lucy A. WARD
  • RECOMBINANT MODIFIED VACCINIA VIRUS ANKARA (MVA) FILOVIRUS VACCINE
    Publication number: 20170304427
    Abstract: The present invention relates to an improved filovirus vaccine comprising a recombinant modified vaccinia virus Ankara-based (MVA-based) vaccine against filovirus infection and to related products, methods and uses. Specifically, the present invention relates to genetically engineered (recombinant) MVA and FPV vectors comprising at least one heterologous nucleotide sequence encoding an antigenic determinant of a Marburg virus (MARV) or Ebola virus glycoprotein. Specifically, the invention relates to recombinant MVA comprising Ebola virus glycoprotein and virion protein 40. The invention also relates to products, methods and uses thereof as well as prime/boost regimens of MVA and genetically engineered (recombinant) FPV, e.g., suitable to induce a protective immune response in a subject.
    Type: Application
    Filed: September 3, 2015
    Publication date: October 26, 2017
    Applicant: Bavarian Nordic A/S
    Inventors: Ariane Volkmann, Robin Steigerwald, Hubertus Hochrein, Ulrike Dirmeier, Henning Lauterbach, Jürgen Hausmann Hausmann
  • METHODS AND COMPOSITIONS FOR INDUCING PROTECTIVE IMMUNITY AGAINST FILOVIRUS INFECTION
    Publication number: 20170290904
    Abstract: The present invention provides compositions, vaccines and methods for inducing protective immunity against filovirus infection, particularly protective immunity against infection of one or more subtypes of Ebola viruses and Marburg virus.
    Type: Application
    Filed: September 3, 2015
    Publication date: October 12, 2017
    Applicants: Bavarian Nordic A/S, Janssen Vaccines & Prevention B.V., The United States of America, as represented by the Secretary Department of Health and Human Ser..
    Inventors: Ariane VOLKMANN, Robin STEIGERWALD, Ulrike DIRMEIER, Maria Grazia PAU, Benoit Christophe CALLENDRET, Lucy A. WARD
  • Single high dose of MVA induces a protective immune response in neonates and infants
    Patent number: 9707291
    Abstract: The invention relates to compositions and methods for inducing a protective immune response against a poxvirus in a human neonate or infant of less than 6 months of age. The invention encompasses administering a single high dose of an MVA to a human neonate or infant of less than 6 months of age, wherein the administration induces protective T- and B-cell responses against a poxvirus in the human neonate or infant.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: July 18, 2017
    Assignee: BAVARIAN NORDIC A/S
    Inventors: Cédric Cheminay, Ariane Volkmann, Paul Chaplin, Mark Suter
  • USE OF OIL AND WATER EMULSIONS FOR INCREASING B CELL RESPONSES WITH MODIFIED VACCINIA ANKARA VIRUS
    Publication number: 20170128561
    Abstract: The invention relates to compositions, uses, and methods for inducing an immune response against a vaccinia virus. The addition of an oil and water emulsion to MVA can vastly increase the B cell response and particularly neutralizing antibodies against vaccinia virus and encoded recombinant antigens. Thus, the addition of an oil and water emulsion to MVA can increase the protective immune response. The invention encompasses administering a dose of an MVA in an oil and water emulsion to an animal, especially a human.
    Type: Application
    Filed: March 12, 2015
    Publication date: May 11, 2017
    Applicant: Bavarian Nordic A/S
    Inventors: Cédric Cheminay, Robin Steigerwald, Ariane Volkmann
  • SINGLE HIGH DOSE OF MVA INDUCES A PROTECTIVE IMMUNE RESPONSE IN NEONATES AND INFANTS
    Publication number: 20160030551
    Abstract: The invention relates to compositions and methods for inducing a protective immune response against a poxvirus in a human neonate or infant of less than 6 months of age. The invention encompasses administering a single high dose of an MVA to a human neonate or infant of less than 6 months of age, wherein the administration induces protective T- and B-cell responses against a poxvirus in the human neonate or infant.
    Type: Application
    Filed: March 14, 2014
    Publication date: February 4, 2016
    Applicant: Bavarian Nordic A/S
    Inventors: Cédric Cheminay, Ariane Volkmann, Paul Chaplin, Mark Suter
  • PREVENTION AND TREATMENT OF INFLAMMATION-INDUCED AND/OR IMMUNE-MEDIATED BONE LOSS
    Publication number: 20110275584
    Abstract: The present invention relates to the use of an 11-?-HSD-type 1 and/or type 2 inhibitor for the manufacture of a pharmaceutical agent for the prevention and/or treatment of inflammation-induced and/or immune-mediated loss of bone and/or cartilage.
    Type: Application
    Filed: May 11, 2011
    Publication date: November 10, 2011
    Applicant: Onepharm Research and Development GmbH
    Inventors: Thomas WILCKENS, Ariane VOLKMANN